Bedrijfsoverzicht
INmune Bio Inc. operates as a clinical-stage immunology company dedicated to developing therapeutic drugs designed to reprogram the innate immune system of patients for the treatment of various diseases within the United States. The enterprise functions within the broader healthcare sector, specifically targeting the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at creating novel biological treatments. At the current time, the company employs 21 individuals and maintains a market capitalization of $31.37M while reporting annual revenue of $50,000 over the trailing twelve months. These financial dimensions indicate that INmune Bio Inc. is a micro-cap entity with negligible current revenue generation relative to its market valuation, suggesting the majority of its value is derived from intellectual property potential and future commercialization prospects rather than existing operational cash flows.
Financiële gezondheid
The company reports trailing twelve-month revenue of $50,000, a net income loss of $-45,933,000, and an EBITDA figure of $-30,785,000, which collectively reveal a significant structural gap where operational expenses far exceed current revenue streams. This substantial disparity between minimal revenue and massive net losses highlights an aggressive cost structure typical of early-stage biotechnology firms investing heavily in clinical trials and research infrastructure. Free cash flow stands at $-13,025,125, indicating that the company is consuming cash reserves rapidly to fund its development pipeline rather than generating surplus liquidity for operational reinvestment or debt servicing. Despite these cash burn rates, the balance sheet holds $24.75M in cash against $1.03M in debt, resulting in a debt-to-equity ratio of 4.40 which suggests a leveraged position reliant on equity financing rather than creditor support. The current ratio is calculated at 3.55, signaling a conservative short-term liquidity posture where current assets significantly exceed current liabilities, providing a buffer against immediate financial obligations. Profitability metrics are stark, with a gross margin of 100.0% reflecting zero cost of goods sold common in early development, an operating margin of -61738.0% driven by high fixed costs, and a profit margin of 0.0% due to the lack of net income relative to sales. Return on Equity is reported at -165.2% and return on assets at -53.7%, metrics that illustrate the negative impact of accumulated losses on shareholder equity and total asset efficiency, indicating that management has yet to achieve positive returns on the capital deployed.
Waarderingsbeoordeling
Trailing twelve-month P/E ratio is unavailable due to negative earnings, while the forward P/E is listed at -1.51, a metric that reflects the market's pricing of future expected losses rather than current profitability. The price-to-book ratio stands at 1.33, indicating that the market values the company at 1.33 times its net asset book value, suggesting a slight premium over the accounting value of its tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 627.41 and an EV/EBITDA of -0.25 further emphasize that traditional earnings-based valuation models are inapplicable, and investors must rely on asset-based or sales-based multiples to assess the company's worth. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $1.09 and a 52-week high of $11.64, placing the current trading range within this wide historical band. The beta value is 0.89, which implies that the stock's price volatility is slightly lower than the broader market average, showing a moderate sensitivity to general market movements despite the underlying high-risk biotechnology nature of the business.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both marked as N/A, precluding any analysis of growth rates or comparisons between the pace of earnings expansion versus revenue expansion. As a non-dividend payer, INmune Bio Inc. reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company retains all available earnings to fund research and development rather than distributing income to shareholders. The absence of dividend payments aligns with the company's strategic profile, where capital is reinvested entirely into the clinical-stage pipeline to advance product candidates for hematologic malignancies, solid tumors, and chronic inflammation. The overall growth and income profile is characterized by a complete lack of historical growth data and zero income distribution, reflecting a pure-play growth strategy dependent on the successful future commercialization of its drug candidates to eventually generate revenue and profitability.